Tandem Cash And Short Term Investments vs Net Debt Analysis
TNDM Stock | USD 49.57 2.47 4.75% |
Tandem Diabetes financial indicator trend analysis is much more than just breaking down Tandem Diabetes Care prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tandem Diabetes Care is a good investment. Please check the relationship between Tandem Diabetes Cash And Short Term Investments and its Net Debt accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Cash And Short Term Investments vs Net Debt
Cash And Short Term Investments vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tandem Diabetes Care Cash And Short Term Investments account and Net Debt. At this time, the significance of the direction appears to have strong relationship.
The correlation between Tandem Diabetes' Cash And Short Term Investments and Net Debt is 0.72. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Net Debt in the same time period over historical financial statements of Tandem Diabetes Care, assuming nothing else is changed. The correlation between historical values of Tandem Diabetes' Cash And Short Term Investments and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Tandem Diabetes Care are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Cash And Short Term Investments i.e., Tandem Diabetes' Cash And Short Term Investments and Net Debt go up and down completely randomly.
Correlation Coefficient | 0.72 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Tandem Diabetes Care balance sheet. This account contains Tandem Diabetes investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Tandem Diabetes Care fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from Tandem Diabetes' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tandem Diabetes Care current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. At this time, Tandem Diabetes' Selling General Administrative is very stable compared to the past year. As of the 7th of June 2024, Tax Provision is likely to grow to about 2.5 M, while Enterprise Value Over EBITDA is likely to drop (20.24).
2021 | 2023 | 2024 (projected) | Interest Expense | 4.3M | 7.6M | 5.8M | Depreciation And Amortization | 13.8M | 15.7M | 9.4M |
Tandem Diabetes fundamental ratios Correlations
Click cells to compare fundamentals
Tandem Diabetes Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tandem Diabetes fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 326.1M | 716.4M | 905.1M | 1.1B | 952.7M | 1.0B | |
Other Current Liab | 71.5M | 70.5M | 84.4M | 77.6M | 84.6M | 88.8M | |
Total Current Liabilities | 99.4M | 103.9M | 131.9M | 165.3M | 195.3M | 205.0M | |
Total Stockholder Equity | 195.0M | 366.3M | 433.1M | 439.9M | 313.6M | 160.8M | |
Other Liab | 17.7M | 27.4M | 34.8M | 36.1M | 41.5M | 43.6M | |
Property Plant And Equipment Net | 48.5M | 69.8M | 77.9M | 179.2M | 164.3M | 172.5M | |
Net Debt | (30.8M) | 133.7M | 243.5M | 247.4M | 356.8M | 374.6M | |
Retained Earnings | (624.8M) | (659.2M) | (634.6M) | (729.2M) | (951.8M) | (904.2M) | |
Accounts Payable | 17.7M | 17.8M | 28.0M | 55.7M | 49.6M | 52.1M | |
Cash | 51.2M | 94.6M | 71.2M | 172.5M | 58.9M | 65.4M | |
Non Current Assets Total | 50.0M | 79.2M | 93.6M | 202.8M | 204.7M | 214.9M | |
Non Currrent Assets Other | 708K | 580K | 9.1M | 19.0M | 37.6M | 39.4M | |
Other Assets | 708K | 29.2M | 9.1M | 10.7M | 12.3M | 12.9M | |
Cash And Short Term Investments | 176.5M | 484.9M | 623.8M | 616.9M | 467.9M | 242.0M | |
Net Receivables | 46.6M | 82.2M | 110.7M | 114.7M | 105.6M | 110.8M | |
Common Stock Total Equity | 59K | 14.3M | 64K | 65K | 74.8K | 71.0K | |
Common Stock Shares Outstanding | 58.5M | 61.0M | 64.3M | 64.1M | 65.0M | 68.2M | |
Short Term Investments | 125.3M | 390.3M | 552.6M | 444.4M | 409.0M | 429.5M | |
Liabilities And Stockholders Equity | 326.1M | 716.4M | 905.1M | 1.1B | 952.7M | 1.0B | |
Non Current Liabilities Total | 31.7M | 246.3M | 340.2M | 447.5M | 443.8M | 466.0M | |
Inventory | 49.1M | 63.7M | 68.6M | 111.1M | 157.9M | 165.8M | |
Other Current Assets | 4.0M | 6.4M | 8.4M | 7.2M | 16.6M | 17.4M | |
Other Stockholder Equity | 819.6M | 1.0B | 1.1B | 1.2B | 1.3B | 669.8M | |
Total Liab | 131.1M | 350.1M | 472.0M | 612.8M | 639.0M | 671.0M | |
Property Plant And Equipment Gross | 48.5M | 50.0M | 77.9M | 179.2M | 217.1M | 228.0M | |
Total Current Assets | 276.1M | 637.2M | 811.5M | 850.0M | 748.0M | 785.4M | |
Accumulated Other Comprehensive Income | 122K | 220K | (616K) | (1.8M) | 1.4M | 1.4M | |
Common Stock | 59K | 62K | 64K | 65K | 66K | 41.6K | |
Property Plant Equipment | 32.9M | 50.0M | 50.4M | 68.6M | 78.8M | 82.8M | |
Current Deferred Revenue | 3.9M | 6.1M | 10.2M | 18.8M | 44.0M | 46.2M | |
Intangible Assets | 777K | 8.8M | 6.6M | 4.6M | 2.8M | 3.5M | |
Net Tangible Assets | 195.0M | 366.3M | 433.1M | 439.9M | 505.9M | 531.2M | |
Retained Earnings Total Equity | (624.8M) | (659.2M) | (634.6M) | (729.2M) | (656.3M) | (689.1M) | |
Capital Surpluse | 819.6M | 1.0B | 1.1B | 1.2B | 1.3B | 776.1M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Tandem Diabetes Care using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Additional Information and Resources on Investing in Tandem Stock
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (2.16) | Revenue Per Share 11.817 | Quarterly Revenue Growth 0.132 | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.